Laurus Labs Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Strong return on equity (ROE 18.3%)
- Efficient capital deployment (ROCE 17.8%)
- Low debt relative to equity (D/E 0.5x)
Concerns
- Premium to sector peers (P/E 90.9x vs industry 54.7x)
- High premium to book value (P/B 18.7x)
- Trading near 52-week high (₹1,949)
Today's Price Action
Laurus Labs Limited (LAURUSLABS) is trading at ₹1,840, unchanged on the day. The session volume matches the 20‑day average at 10,74,891 shares, indicating that participation is in line with recent trading activity and that there is no immediate surge in buying or selling pressure.
Valuation Snapshot
The stock’s trailing P/E stands at 95.8, markedly higher than the sector average, which is effectively zero because many peers are either loss‑making or have no earnings. A price‑to‑book ratio of 0 and a return on equity of 18.3 % suggest that the market is pricing the firm at a premium relative to its book value while it continues to generate respectable equity returns.
Key Levels to Watch
The current price sits just below the 52‑week high of ₹1,939 and well above the 52‑week low of ₹823, positioning the share in the upper‑half of its annual range. Open‑interest data (not disclosed here) has historically shown clustering around the ₹1,800‑₹1,850 band, providing a reference zone for potential liquidity concentration.
Chart Pattern
In the daily chart’s last ten sessions, a bullish hammer appeared three days ago, followed by a bearish hanging man and a bearish engulfing pattern five days ago. These candlesticks were formed on the daily timeframe and collectively illustrate short‑term indecision, with the latter two patterns hinting at a possible shift toward downside momentum.
Data Summary
Key metrics for LAURUSLABS today include a flat price of ₹1,840, a P/E of 95.8, a zero P/B, and an ROE of 18.3 %. Trading volume aligns with the 20‑day average at 10,74,891 shares, while the share remains near the upper end of its 52‑week range.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,110 | ₹96K Cr | 16.2 | 4.3 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
LAURUSLABS · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 27.18% | 27.18% | 27.18% | 27.18% | 27.62% | 27.62% |
| FII | 25.39% | 25.98% | 25.67% | 26.08% | 25.56% | 25.51% |
| DII | 11.13% | 11.78% | 13.56% | 13.05% | 12.74% | 11.78% |
| Public | 36.30% | 35.07% | 33.59% | 33.69% | 34.09% | 35.09% |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Interim Dividend - Rs 1.20 Per Share
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Interim Dividend - Re 0.80 Per Sh
Interim Dividend - Rs 0.80 Per Share
Interim Dividend - Rs 0.40 Per Share
Annual General Meeting
Interim Dividend - Re 0.40 Per Share
Interim Dividend - Re 0.40 Per Share
Annual General Meeting
Latest News
All newsMSCI rejig 2026 to boost Laurus, Lenskart, Adani Energy, Groww
*MSCI rejig 2026 to boost Laurus, Lenskart, Adani Energy, Groww* — MSCI’s upcoming index reshuffle in 2026 is expected to bring **significant FII inflows** into Laurus Labs, Lenskart, Adani Energy Solutions, and Groww. These stocks are set for higher passive fund flows due to increased index weight. Meanwhile, **Reliance faces a weight cut**, potentially triggering outflows. The move reflects shifting sectoral dynamics in Indian equities. 📊 *STOCKS:* LAURUSLABS, LENSKART, ADANIENERGY, GROWW, RELIANCE | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #MSCI
Adani Energy, Laurus Labs enter MSCI index; Astral, SBI Cards exit
*Adani Energy, Laurus Labs, Groww, and Lenskart are entering the MSCI India index, while Astr/ and SBI Cards are exiting.* This rebalance may trigger passive fund inflows of **$150 million** into the added stocks. Index rejigs often lead to short-term volatility as FPIs adjust portfolios. Outgoing stocks may see temporary selling pressure. 📊 *STOCKS:* ADANITRANS, LAURUSLABS, ASTRAL, SBICARD | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #MSCI
Laurus Labs, Adani Energy added to MSCI India Index
*Laurus Labs, Adani Energy added to MSCI India Index.* MSCI added Laurus Labs, Adani Energy, Lenskart, and Groww parent to its India Index in a quarterly rebalancing. Index inclusion may attract passive inflows from global ETFs tracking MSCI benchmarks. **No immediate financial impact**, but improves visibility among foreign investors. 📊 *STOCKS:* $LAURUSLABS $ADANIENERGY | 🏢 *SECTOR:* Indices | #MEDIUMIMPACT #indexinclusion
MSCI India Index adds Adani Energy, Laurus Labs, Lenskart, Groww
*MSCI India Index adds Adani Energy, Laurus Labs, Lenskart, Groww* and removes 3 stocks. The change may trigger passive inflows into added stocks, especially **Adani Energy** and **Laurus Labs**. Global funds tracking MSCI may rebalance portfolios, impacting near-term demand. Lenskart and Groww inclusion reflects growing weight of private-to-public transitions. 📊 *STOCKS:* $LAURUSLABS $ADANIENERGY | 🏢 *SECTOR:* Indices | #MEDIUMIMPACT #IndexRebalance
MSCI reshuffle adds Laurus Labs, drops SBI Card
*MSCI reshuffle adds Laurus Labs, drops SBI Card*. Laurus Labs, along with three others, has been added to the MSCI India Index, effective next rebalance. SBI Card, Astral, and BKT are being removed, potentially triggering passive fund outflows. Inclusion often brings **$50-70 million** in foreign inflows, while exclusion may see outflows. 📊 *STOCKS:* $LAURUSLABS $ASTRAL $BKT $SBICARD | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #MSCI
Billionbrains Garage, Laurus Labs added to MSCI India Index
Billionbrains Garage and Laurus Labs will be added to the MSCI India Index, effective next rebalance. Inclusion often attracts **passive inflows** from global funds tracking MSCI benchmarks. This could boost liquidity and valuations for both stocks, especially Billionbrains Garage, a lesser-known entity. Index reshuffle impacts portfolio allocations for major ETFs. 📊 *STOCKS:* BILLIONBRAI, LAURUSLABS | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #IndexInclusion
Laurus Labs hosts analyst and investor call.
*Laurus Labs hosts analyst and investor call.* The company provided updates during its recent investor meet, discussing operational performance and future outlook. No major financial announcements or guidance changes were disclosed. The session focused on Q4 results and segment-wise demand trends. 📊 *STOCKS:* $LAURUSLABS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Laurus Labs, Biocon among MSCI index inclusion candidates
*Laurus Labs, Biocon among MSCI India index inclusion candidates.* Inclusion in the MSCI India Standard Index could attract **$200–300 million** in passive inflows. Stocks not yet confirmed but seen as strong contenders based on market cap and liquidity. A final decision will be announced by MSCI next week. 📊 *STOCKS:* LAURUSLABS, BIOCON | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #MSCI
MSCI rejig may bring ₹30,000 cr inflows; Laurus, Biocon to benefit
*MSCI's August index rejig could trigger over **₹30,000 crore** in foreign inflows into Indian markets.* Laurus Labs and Biocon are leading candidates for inclusion, potentially drawing passive fund flows. Stocks on the watchlist often see pre-rejig accumulation by FPIs. Inclusion may boost near-term demand and liquidity. 📊 *STOCKS:* LAURUSLABS, BIOCON | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #MSCI
Laurus, Biocon, SAIL eyed for MSCI India index inclusion
*Laurus, Biocon, SAIL eyed for MSCI India index inclusion.* Stocks under consideration may see **$100–150 million** in passive inflows if included. MSCI's decision could boost FII interest and trading volumes ahead of rebalance. Final announcement expected by month-end. 📊 *STOCKS:* LAURUSLABS, BIOCON, SAIL | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #MSCI
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.8K Cr 7.6% | ₹1.7K Cr 5.3% | ₹1.6K Cr 8.7% | ₹1.7K Cr 21.6% | ₹1.4K Cr 15.6% | ₹1.2K Cr 2.4% | ₹1.2K Cr 17.0% | ₹1.4K Cr |
| Op. Profit | ₹480 Cr 19.1% | ₹403 Cr 5.5% | ₹382 Cr 9.3% | ₹421 Cr 47.7% | ₹285 Cr 60.1% | ₹178 Cr 4.1% | ₹171 Cr 29.0% | ₹241 Cr |
| OPM | 27.0% 12.5% | 24.0% 0.0% | 24.0% 0.0% | 24.0% 20.0% | 20.0% 33.3% | 15.0% 7.1% | 14.0% 17.6% | 17.0% |
| Net Profit | ₹252 Cr 29.9% | ₹194 Cr 19.8% | ₹162 Cr 30.5% | ₹233 Cr 150.5% | ₹93 Cr 365.0% | ₹20 Cr 53.8% | ₹13 Cr 82.7% | ₹75 Cr |
| EPS (₹) | 4.66 29.1% | 3.61 19.5% | 3.02 30.3% | 4.33 153.2% | 1.71 362.2% | 0.37 60.9% | 0.23 83.6% | 1.4 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6.8K Cr 22.7% | ₹5.6K Cr 10.2% | ₹5.0K Cr 16.6% | ₹6.0K Cr 22.4% | ₹4.9K Cr 2.5% | ₹4.8K Cr 70.0% | ₹2.8K Cr 23.6% | ₹2.3K Cr 11.5% | ₹2.1K Cr 7.9% | ₹1.9K Cr |
| Expenses | ₹5.0K Cr 11.8% | ₹4.5K Cr 5.6% | ₹4.3K Cr 4.2% | ₹4.4K Cr 26.7% | ₹3.5K Cr 7.7% | ₹3.3K Cr 44.0% | ₹2.3K Cr 17.1% | ₹1.9K Cr 17.8% | ₹1.6K Cr 9.7% | ₹1.5K Cr |
| Op. Profit | ₹1.8K Cr 69.2% | ₹1.1K Cr 35.4% | ₹779 Cr 51.1% | ₹1.6K Cr 11.8% | ₹1.4K Cr 8.2% | ₹1.6K Cr 174.7% | ₹565 Cr 58.3% | ₹357 Cr 13.8% | ₹414 Cr 1.5% | ₹408 Cr |
| OPM | 26.0% 36.8% | 19.0% 26.7% | 15.0% 42.3% | 26.0% 10.3% | 29.0% 9.4% | 32.0% 60.0% | 20.0% 25.0% | 16.0% 20.0% | 20.0% 4.8% | 21.0% |
| Other Income | ₹47 Cr 37.3% | ₹75 Cr 212.5% | ₹24 Cr 300.0% | ₹6 Cr 57.1% | ₹14 Cr 39.1% | ₹23 Cr 360.0% | ₹5 Cr 66.7% | ₹15 Cr 48.3% | ₹29 Cr 9.4% | ₹32 Cr |
| Interest | ₹171 Cr 20.8% | ₹216 Cr 18.0% | ₹183 Cr 10.9% | ₹165 Cr 61.8% | ₹102 Cr 50.0% | ₹68 Cr 24.4% | ₹90 Cr 2.3% | ₹88 Cr 10.0% | ₹80 Cr 20.0% | ₹100 Cr |
| Depreciation | ₹480 Cr 11.6% | ₹430 Cr 11.7% | ₹385 Cr 18.8% | ₹324 Cr 29.1% | ₹251 Cr 22.4% | ₹205 Cr 9.6% | ₹187 Cr 14.0% | ₹164 Cr 31.2% | ₹125 Cr 17.9% | ₹106 Cr |
| PBT | ₹1.2K Cr 144.2% | ₹484 Cr 105.1% | ₹236 Cr 78.7% | ₹1.1K Cr 2.3% | ₹1.1K Cr 16.7% | ₹1.3K Cr 342.5% | ₹294 Cr 145.0% | ₹120 Cr 49.4% | ₹237 Cr 1.3% | ₹234 Cr |
| Tax % | 25.0% 7.4% | 27.0% 6.9% | 29.0% 3.6% | 28.0% 21.7% | 23.0% 4.2% | 24.0% 84.6% | 13.0% 40.9% | 22.0% 24.1% | 29.0% 52.6% | 19.0% |
| Net Profit | ₹890 Cr 148.6% | ₹358 Cr 121.0% | ₹162 Cr 79.6% | ₹793 Cr 4.7% | ₹832 Cr 15.4% | ₹984 Cr 285.9% | ₹255 Cr 171.3% | ₹94 Cr 44.0% | ₹168 Cr 11.6% | ₹190 Cr |
| EPS (₹) | 16.46 147.9% | 6.64 122.8% | 2.98 79.7% | 14.67 4.7% | 15.4 16.0% | 18.33 284.3% | 4.77 171.0% | 1.76 44.3% | 3.16 12.2% | 3.6 |
| Div Payout | 12.0% 33.3% | 18.0% 33.3% | 27.0% 92.9% | 14.0% 7.7% | 13.0% 18.2% | 11.0% 10.0% | 10.0% 41.2% | 17.0% 88.9% | 9.0% 12.5% | 8.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹108 Cr 0.0% | ₹108 Cr 0.0% | ₹108 Cr 0.0% | ₹108 Cr 0.9% | ₹107 Cr 0.0% | ₹107 Cr 0.0% | ₹107 Cr 0.9% | ₹106 Cr 0.0% | ₹106 Cr 0.0% | ₹106 Cr |
| Reserves | ₹4.7K Cr 7.6% | ₹4.4K Cr 9.0% | ₹4.0K Cr 1.9% | ₹3.9K Cr 21.1% | ₹3.2K Cr 30.3% | ₹2.5K Cr 49.7% | ₹1.7K Cr 14.5% | ₹1.5K Cr 5.4% | ₹1.4K Cr 12.4% | ₹1.2K Cr |
| Borrowings | ₹2.2K Cr 20.0% | ₹2.8K Cr 7.3% | ₹2.6K Cr 27.9% | ₹2.0K Cr 13.4% | ₹1.8K Cr 19.9% | ₹1.5K Cr 37.3% | ₹1.1K Cr 4.2% | ₹1.0K Cr 5.7% | ₹980 Cr 16.4% | ₹842 Cr |
| Other Liabilities | ₹2.4K Cr 14.2% | ₹2.1K Cr 23.5% | ₹1.7K Cr 5.7% | ₹1.6K Cr 12.6% | ₹1.8K Cr 10.1% | ₹1.7K Cr 85.5% | ₹901 Cr 22.3% | ₹737 Cr 33.0% | ₹554 Cr 15.2% | ₹481 Cr |
| Total Liabilities | ₹9.4K Cr 0.8% | ₹9.3K Cr 11.3% | ₹8.4K Cr 9.5% | ₹7.7K Cr 9.9% | ₹7.0K Cr 21.2% | ₹5.8K Cr 53.4% | ₹3.8K Cr 12.6% | ₹3.3K Cr 10.4% | ₹3.0K Cr 13.7% | ₹2.7K Cr |
Assets | ||||||||||
| Fixed Assets | ₹4.2K Cr 2.9% | ₹4.1K Cr 6.0% | ₹3.9K Cr 14.1% | ₹3.4K Cr 28.5% | ₹2.7K Cr 22.2% | ₹2.2K Cr 25.8% | ₹1.7K Cr 6.0% | ₹1.6K Cr 10.0% | ₹1.5K Cr 20.4% | ₹1.2K Cr |
| CWIP | ₹541 Cr 18.1% | ₹458 Cr 8.3% | ₹423 Cr 23.2% | ₹551 Cr 32.2% | ₹813 Cr 124.6% | ₹362 Cr 440.3% | ₹67 Cr 39.1% | ₹110 Cr 32.5% | ₹163 Cr 14.0% | ₹143 Cr |
| Investments | ₹261 Cr 12.0% | ₹233 Cr 87.9% | ₹124 Cr 148.0% | ₹50 Cr 61.3% | ₹31 Cr 933.3% | ₹3 Cr 0.0% | ₹3 Cr 0.0% | ₹3 Cr 0.0% | ₹3 Cr 0.0% | ₹3 Cr |
| Other Assets | ₹4.4K Cr 3.3% | ₹4.5K Cr 14.5% | ₹4.0K Cr 8.2% | ₹3.7K Cr 5.2% | ₹3.5K Cr 8.0% | ₹3.2K Cr 64.6% | ₹2.0K Cr 22.9% | ₹1.6K Cr 16.1% | ₹1.4K Cr 7.2% | ₹1.3K Cr |
| Total Assets | ₹9.4K Cr 0.8% | ₹9.3K Cr 11.3% | ₹8.4K Cr 9.5% | ₹7.7K Cr 9.9% | ₹7.0K Cr 21.2% | ₹5.8K Cr 53.4% | ₹3.8K Cr 12.6% | ₹3.3K Cr 10.4% | ₹3.0K Cr 13.7% | ₹2.7K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹602 Cr 9.6% | ₹666 Cr 33.0% | ₹994 Cr 9.1% | ₹911 Cr 24.3% | ₹733 Cr 111.2% | ₹347 Cr 16.4% | ₹298 Cr 12.9% | ₹342 Cr 3.0% | ₹332 Cr 82.4% | ₹182 Cr |
| Investing CF | ₹-680 Cr 17.3% | ₹-822 Cr 17.6% | ₹-997 Cr 9.1% | ₹-914 Cr 2.9% | ₹-941 Cr 325.8% | ₹-221 Cr 12.6% | ₹-253 Cr 34.1% | ₹-384 Cr 32.9% | ₹-289 Cr 7.4% | ₹-312 Cr |
| Financing CF | ₹39 Cr 84.4% | ₹250 Cr 1025.9% | ₹-27 Cr 190.0% | ₹30 Cr 88.2% | ₹255 Cr 299.2% | ₹-128 Cr 184.4% | ₹-45 Cr 207.1% | ₹42 Cr 177.8% | ₹-54 Cr 152.4% | ₹103 Cr |
| Net Cash Flow | ₹-39 Cr 141.9% | ₹93 Cr 410.0% | ₹-30 Cr 211.1% | ₹27 Cr 42.6% | ₹47 Cr 4800.0% | ₹-1 Cr | ₹0 Cr 100.0% | ₹1 Cr 110.0% | ₹-10 Cr 63.0% | ₹-27 Cr |
| Free Cash Flow | ₹61 Cr 710.0% | ₹-10 Cr 266.7% | ₹6 Cr 82.4% | ₹34 Cr 30.6% | ₹49 Cr 60.8% | ₹125 Cr 184.1% | ₹44 Cr 189.8% | ₹-49 Cr 189.1% | ₹55 Cr 138.2% | ₹-144 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 132d 10.0% | 120d 25.0% | 96d 4.0% | 100d 1.0% | 99d 2.9% | 102d 9.7% | 113d 11.9% | 101d 7.3% | 109d 19.8% | 91d |
| Inventory Days | 285d 2.9% | 277d 24.8% | 222d 24.2% | 293d 10.2% | 266d 13.7% | 234d 16.4% | 201d 0.0% | 201d 8.1% | 186d 5.7% | 176d |
| Days Payable | 141d 10.8% | 158d 68.1% | 94d 35.6% | 146d 26.6% | 199d 25.2% | 159d 10.4% | 144d 34.6% | 107d 11.5% | 96d 6.7% | 90d |
| Cash Conv. Cycle | 276d 15.0% | 240d 7.1% | 224d 9.3% | 247d 48.8% | 166d 6.2% | 177d 4.1% | 170d 12.8% | 195d 2.0% | 199d 11.8% | 178d |
| Working Capital Days | 43d 2.4% | 42d 28.8% | 59d 37.2% | 43d 0.0% | 43d 186.7% | 15d 150.0% | 6d 154.5% | -11d 466.7% | 3d 84.2% | 19d |
| ROCE | 9.0% 28.6% | 7.0% 69.6% | 23.0% 11.5% | 26.0% 35.0% | 40.0% 185.7% | 14.0% 75.0% | 8.0% 42.9% | 14.0% 12.5% | 16.0% 0.0% | 16.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Laurus Labs Limited
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]
HealthcarePharmaceuticals & Biotechnology